Blue Jet Healthcare Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: BLUEJET BSE: 544009
₹538.05
Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #45 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

CompanyMarket cap (₹ Cr)PE (TTM)ROE1Y returnDiv. yieldQualityValuationMomentum
Sun Pharmaceutical Industries Limited 435,863 146.5 13.7% 11.0% — 72 8 30
Divi's Laboratories Limited 246,660 83.9 15.3% 62.7% 0.32% 70 4 51
Torrent Pharmaceuticals Limited 162,454 78.2 12.2% 34.6% 0.79% 56 0 31
Zydus Lifesciences Limited 115,910 33.3 17.3% 17.2% 0.09% 74 24 84
Cipla Limited 108,736 35.4 11.2% -11.0% 0.97% 73 29 62
Laurus Labs Limited 106,969 122.5 17.1% 127.1% — 78 24 53
Mankind Pharma Limited 103,406 47.4 11.7% 2.6% — 68 12 86
Dr. Reddy's Laboratories Limited 102,916 154.7 10.9% -0.9% — 62 33 71
Blue Jet Healthcare Limited (this stock) 9,333 39.7 18.2% -18.7% 0.22% 74 0 28

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value
₹9,272 Cr
EV / EBITDA
26.7x
EV / Sales
10.47x
Market cap / Sales
10.54x
Earnings yield
2.52%

Quarterly Financials

↓ Negative
Quarterly Revenue

Jun 2026 quarterly revenue is Rs 308 Cr, down 15.1% YoY.

↓ Negative
Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 78 Cr, down 14.2% YoY.

Period endRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)Basic EPS
June 30, 2026 293 106 78 ₹4.5100
March 31, 2026 235 87 64 ₹3.7100
Dec. 31, 2025 192 54 40 ₹2.3200
Sept. 30, 2025 165 69 52 ₹3.0100
June 30, 2025 355 123 91 ₹5.2600
March 31, 2025 340 147 110 ₹6.3500
Dec. 31, 2024 318 132 99 ₹5.7080
Sept. 30, 2024 208 77 58 ₹3.3640
June 30, 2024 163 49 38 ₹2.1800
March 31, 2024 184 54 39 ₹2.2900
Dec. 31, 2023 167 44 32 ₹1.8500
Sept. 30, 2023 181 64 48 ₹2.7600

Quarterly income statement (standalone, ₹ Cr)

IndicatorJun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
Total income (before exceptional items)308258206190363353332220172193174190
Operating revenue293235192165355340318208163184167181
Other income1523132481213129978
Operating expenses195163146111234200194139119131112119
Operating profit987147551211401246944535563
Operating profit margin33.5%30.4%24.4%33.2%34.1%41.1%39.0%33.4%27.2%28.8%32.7%34.5%
Depreciation766665553886
Interest110510000000
Exceptional items, gain / (loss)——————————-10—
Profit before tax1068754691231471327749544464
Tax282314173237341912141216
Net profit7864405291110995838403248
EPS4.513.712.323.015.266.355.713.362.182.291.852.76
Net profit (TTM)235248294352359305235168157———
EPS (TTM)13.5514.3016.9420.3320.6817.6013.549.689.08———

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year endedRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)
March 31, 2026 947 333 248
March 31, 2025 1,030 406 305
March 31, 2024 712 220 164

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

IndicatorCAGR 3YCAGR 5YMar 26Mar 25Mar 24
Total income (before exceptional items) — — 1,016†1,076†—
Operating revenue — — 9471,030712
Other income — — 69†46†—
Operating expenses — — 653†652†—
Operating profit — — 294†378†—
Operating profit margin — — 31.0%†36.7%†—
Depreciation — — 24†18†—
Interest — — 6†0†—
Exceptional items, gain / (loss) — — 0†0†—
Profit before tax — — 333406220
Tax — — 85†101†—
Net profit — — 248305164
EPS — — 14.30†17.60†—

† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

RatioMar 26Mar 25Mar 24
Operating margin31.0%†36.7%†—
EBIT margin35.8%†39.4%†—
PBT margin35.1%39.4%30.9%
Net margin26.2%29.6%23.0%
Interest coverage54.30x†4144.87x†—
Dividend payout8.4%†5.7%†—
Earnings retention91.6%†94.3%†—
Current ratio4.21x3.93x—
Quick ratio3.38x2.90x—
Debt to equity0.00x0.00x—
Return on equity18.2%26.9%—
Return on assets15.1%21.5%—
Return on capital employed24.0%†35.0%†—
Asset turnover0.58x0.73x—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year endedOperating (₹ Cr)Investing (₹ Cr)Financing (₹ Cr)Capex (₹ Cr)Free Cash Flow (₹ Cr)
March 31, 2026 334 -276 -31 0 334
March 31, 2025 46 -35 -19 80 -34
March 31, 2024 241 -264 -2 173 68

Balance Sheet (standalone)

Year endedTotal Assets (₹ Cr)Total Equity (₹ Cr)Reserves (₹ Cr)Borrowings, Current (₹ Cr)Borrowings, Non-current (₹ Cr)Current Assets (₹ Cr)Current Liabilities (₹ Cr)Cash & Equivalents (₹ Cr)Net Block (₹ Cr)Inventory (₹ Cr)
March 31, 2026 1,641 1,360 1,325 0 0 957 227 61 314 187
March 31, 2025 1,418 1,133 1,098 0 0 1,006 256 33 260 264
March 31, 2024 — — — — — — — — — —

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.